Mucus-producing cells are very characteristic of epithelial tissues. Mucus covers the surface of most epithelia and plays a fundamental role in the lubrication and protection of mucosal surfaces (Neutra and Forstner, 1987) . Mucus is biochemically complex and heterogeneous, its major components being mucin glycoproteins (Neutra and Forstner, 1987; Kaliner, 1991) . Mucin glycoproteins are characterised by a high carbohydrate content (greater than 80%) and core peptides that are rich in Thr, Ser, Pro, Ala and Gly (Kaliner, 1991; Kim et al., 1991; Neutra and Forstner, 1987; Wesley et al., 1985) . As more than 90% of pancreatic cancers are adenocarcinomas of ductal origin, these cancers frequently contain mucin-producing cells as detected by histochemical stains, whereas normal pancreatic tissue constitutes only a minor portion of cells in the secretory ducts (Roberts and Burns, 1972) . The altered structure of mucins in pancreatic carcinomas has been extensively documented at the oligosaccharide level (Balague et al., 1994; Schiissler et al., 1991; Takahashi et al., 1988; Xu et al., 1989) . Mucins are also often detectable in the serum of patients suffering from pancreatic cancer; these include the blood group antigen sialylated Lewisa, which is the epitope for the antibody detecting CA19-9 (Magnani et al., 1983) and ThomsenFriedenreich antigen (galactose , Rhodes, 1988, 1990) , which is the epitope for the lectin peanut agglutinin (PNA). Many reports have evaluated the practicality of using tumour markers such as CA19-9, CEA, CA50, CA242, CA494 and others for the serological diagnosis of pancreatic cancer and the follow-up of patients after tumour resection for pancreatic cancer (Frebourg et al., 1988; Freiss et al., 1993; Habib et al., 1986; Haglund et al., 1986; Kalser et al., 1978; Lucarotti et al., 1991; Nilsson et al., 1992; Ohshio et al., 1990; Von Rosen et al., 1993; Safi et al., 1986; Toshkov et al., 1994) . In 1992, Parker et al. firstly reported a new enzyme-linked antibody sandwich assay (CAM 17.1/WGA) using the monoclonal antibody CAM 17.1, which was generated after immunisation with Coll 2 -23 colorectal cancer cells. CAM 17.1 is an immunoglobulin M antibody with high specificity for intestinal mucus, particularly in the colon, small intestine, biliary tract and pancreas (Makin et al., 1984; Raouf et al., 1991) . Erythrocyte agglutination studies revealed that the epitope detected by the CAM 17.1 antibody is a sialysated blood group antigen and is probably related to the I antigen, which is absent from cord blood (Parker et al., 1992) .
In We studied sera from patients with pancreatic cancer (n=91: ductal adenocarcinoma, n = 79; cystadenocarcinoma, n = 12), chronic pancreatitis (n = 93), colorectal cancer (n = 30), gastric cancer (n =20) and from blood donors (n = 30). All cases of carcinoma were confirmed histologically; TNM staging was available in all but two cases.
Immunohistochemistry
Frozen sections were fixed in ice-cold methanol for 10 min, washed in phosphate-buffered saline (PBS) and incubated with normal goat serum (10% in PBS). After washing three times in PBS, sections were incubated with the primary antibody CAM 17. 1-Ab for 1 h (purified antibody (100 jug ml -'), diluted 1:100). After two washes with PBS, sections were incubated for 30 min with peroxidaseconjugated secondary antibody anti-mouse (DAKO, Santa Barbara, CA, USA). For the negative control, a monoclonal mouse antibody (IgM, Dako) was used in the same concentration. Visualisation of the immunocomplexes was performed with DAB (diaminobenzidine, Sigma, Taufkirchen, Germany). The cells were counterstained with haematoxylin, mounted with glycerol gelatin and then viewed by microscopy. The negative control showed no background staining.
Flow cytometric analysis Following trypsination, cells were washed twice in PBS 1% bovine serum albumin (BSA), resuspended and seeded into microtitre plates at a final concentration of I05 cells per well.
In order to reduce non-specific binding, 10 pl of goat immunoglobulin (3 mg ml-') was added to each well. After one washing step, the cells were incubated with the unconjugated monoclonal antibodies, at the same concentrations as used for immunohistochemistry, for 30 min on ice, washed twice with 200 ,ul of PBS-1% BSA and stained with FITC-F(ab')2 fragment-conjugated goat anti-mouse IgM (Dianova) for an additional 20 min. Following two washes with PBS-1% BSA, cells were fixed with 1% paraformaldehyde. For CA19-9 and CEA determination CA19-9 was measured with a commercial, solid-phase, twosite immunoradiometric assay (EIA CIA19-9, CIS, Dreieich, Germany). As described in other studies, 37 U ml-' was considered the upper normal limit of the CA 19-9 assay (Safi et al., 1986) . The concentration of CEA was also determined using a commercial, solid-phase, two-site enzyme immunoassay (EIA, Dreieich, Germany). In our study, the upper normal limit of CEA was considered to be 3.0 ng ml-' (O'Dwyer et al., 1988 Figure 3) . In adenocarcinoma and cystadenocarcinoma, the sensitivity was 63% and 92% respectively. The serum CAM 17.1 levels seemed to be dependent on the tumour stage: the more advanced the disease, the higher the serum CAM 17.1 levels (Figure 4) . In healthy blood donors and patients with chronic pancreatitis, CAM 17.1 exceeded the cut-off level in 7.3% (9/123). The specificity of CAM 17.1 in healthy volunteers, patients with chronic pancreatitis, colorectal cancer patients and gastric cancer patients was 100% (0/30), 90% (84/93), 93% (28/30) and 80% (16/20) respectively (Table I and Figure 3) . CAM 17.1 serum levels in patients with pancreatic cancer were not affected by the tumour differentiation and the presence or absence of clinical jaundice. No correlation was found between bilirubin levels and CAM 17.1, as well as CA 19-9, levels (Spearman's rank correlation test). The sensitivity increased with increasing tumour stage (Table  II) . Interestingly, there was a significant difference between resectability and elevated CAM 17.1 levels; in the group of patients with unresectable pancreatic adenocarcinomas the sensitivity of CAM 17.1 was 78%, whereas only 49% of the resectable patients showed elevated CAM 17.1 serum levels (Table II) .
Comparison of CAM 17.1 with CA 19-9 and CEA The sensitivities of CAM 17.1 and CA 19-9 in detecting pancreatic cancer were 67% and 76% respectively (P=0.22, not significant). In these patients, both markers showed a significant positive correlation (r = 0.91, P> 0.001) (Figure 5) . CEA was elevated in only 51% (Table I) . Neither CAM 17.1 nor CA 19-9 serum levels were influenced by jaundice. CA 19-9 was dependent on tumour differentiation and CAM 17.1 was significantly more frequently positive in advanced diseases and unresectable cases. There was a tendency for median survival times in CAM 17.1-or CA 19-9-negative patients to be higher than in positive cases (Table II) .
Comparison of CAM 17.1 and CA 19-9 using receiver operating characteristic curve analysis (ROC) revealed no statistically significant difference between these two tumour markers.
The specificity of CAM 17.1 for pancreatic cancer in patients with colorectal or gastric cancer was significantly higher than the specificity of CA 19-9 (CAM 17.1, 88%; CA 19-9, 58%; P>0.001). Also, in patients with chronic pancreatitis, the most important control group for pancreatic cancer, the specificity of CAM 17.1 was significantly higher than the specificity of CA 19-9 (90% and 78%; P>0.05). The combined evaluation of CAM 17.1 and CA 19-9 in patients with pancreatic cancer or chronic 10 000 (Frebourg et al., 1988; Haglund et al., 1986; Lucarotti et al., 1991; Magnani et al., 1983; Ohshio et al., 1990; Von Rossen et al., 1993; Safi et al., 1986; Toshkov et al., 1994) . The monoclonal antibody CAM 17.1 detects a mucus glycoprotein with a high specificity for intestinal mucus, particularly in the colon, small intestine, biliary tract and pancreas (Makin et al., 1984; Raouf et al., 1991) . Immunohistological analysis of pancreatic tissue specimens revealed an overexpression of the CAM 17.1 antigen in pancreatic cancer. In pancreatic carcinoma cell lines, we observed a high expression of CAM 17.1. Taken together with high CAM 17.1 levels in the culture supernatants, we were able to demonstrate a high turnover rate of CAM 17.1 in these cell lines. These in vitro data correspond well with the observation that CAM 17.1 serum levels increase with increasing tumour stages and resectability, suggesting that in CAM 17.1-positive cases, the serum levels reflect the amount of tumour cells burden. In comparison with CA 19-9, CAM 17.1 had a similar sensitivity and a higher specificity, especially in patients with chronic pancreatitis. This could offer a better opportunity to distinguish benign from malignant pancreatic tumours because in clinical practice it is often difficult to distinguish patients with chronic pancreatitis combined with an inflammatory enlargement of the pancreatic head from patients with malignant pancreatic tumours.
CEA, the oldest commercially available and widely used serum tumour marker, has a low rate of accuracy in detecting patients with pancreatic cancer and in ruling out patients suffering from non-malignant pancreatic diseases. Therefore, it is not reliable for monitoring pancreatic cancer, whereas in carcinomas of the colon its value is undisputed (Northover, 1986) .
In conclusion, we have described the cellular expression and the release of a new tumour-associated antigen which is detected by the monoclonal antibody CAM 17.1. We further investigated the potential use of this tumour marker in pancreatic cancer, and in comparison to CA 19-9 we found a significantly higher specificity and a similar sensitivity of CAM 17.1. These data suggest that CAM 17.1, besides having a similar sensitivity to CA 19-9, provides additional information for use in the differentiation between chronic pancreatitis and pancreatic carcinoma. Further studies in larger series of patients will be carried out to confirm the data presented.
